Filing Flows › Century Therapeutics (IPSC) › Stock forecast & fair value
Century Therapeutics (IPSC) stock forecast and price target
Century Therapeutics (IPSC) trades at $1.68. 4 analysts' median price target is $4.50 (+168%), from $2.00 to $8.00.
Century Therapeutics' latest quarter
Century Therapeutics, Q1 2025: revenue $109M (128× year over year), operating margin 67.9%, net earnings $76.6M, operating cash flow −$34.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for IPSC stock?
The median of 4 analysts' 12-month targets is $4.50, +168% from $1.68; the range is $2.00 to $8.00. The average rating is none.
Does Century Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 100% of the quarters on record.
Is IPSC stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.